Group 1 - The core viewpoint of the news is that Kew Flower Pharmaceutical experienced a slight increase in stock price and trading volume, with notable changes in financing and stockholder dynamics [1][2] Group 2 - As of January 9, Kew Flower Pharmaceutical's stock price rose by 0.74%, with a trading volume of 37.18 million yuan. The financing buy-in amount was 2.92 million yuan, while the financing repayment was 2.43 million yuan, resulting in a net financing buy-in of 489,200 yuan [1] - The total financing and securities balance for Kew Flower Pharmaceutical reached 135 million yuan, with the financing balance accounting for 1.51% of the circulating market value, indicating a low level compared to the past year [1] - On the short-selling side, Kew Flower Pharmaceutical had a short-selling repayment of 100 shares and no short-selling sales, with a short-selling balance of 2.05 million yuan, which is above the 80th percentile level over the past year, indicating a high level [1] Group 3 - As of December 31, the number of shareholders for Kew Flower Pharmaceutical was 48,000, a decrease of 2.04% from the previous period, while the average circulating shares per person increased by 2.08% to 12,166 shares [2] - For the period from January to September 2025, Kew Flower Pharmaceutical reported a revenue of 1.684 billion yuan, a year-on-year decrease of 43.24%, and a net profit attributable to shareholders of -33.54 million yuan, a decrease of 105.72% year-on-year [2] - Since its A-share listing, Kew Flower Pharmaceutical has distributed a total of 4.045 billion yuan in dividends, with 1.752 billion yuan distributed in the last three years [2] Group 4 - As of September 30, 2025, among the top ten circulating shareholders of Kew Flower Pharmaceutical, E Fund CSI Dividend ETF ranked fifth with 3.4008 million shares, an increase of 239,600 shares from the previous period [2] - Hong Kong Central Clearing Limited ranked seventh with 2.8412 million shares, a decrease of 128,700 shares from the previous period [2] - The eighth largest circulating shareholder, China Merchants CSI Dividend ETF, held 2.8382 million shares, an increase of 234,900 shares, while the ninth largest, Southern CSI 1000 ETF, held 2.6757 million shares, a decrease of 20,300 shares [2]
葵花药业1月9日获融资买入291.52万元,融资余额1.33亿元